<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-29014" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Sickle Cell Crisis</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Borhade </surname>
            <given-names>Mahesh B.</given-names>
          </name>
          <aff>Cape Fear Valley Hospital / Person Memorial Hospital</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Patel</surname>
            <given-names>Preeti</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Kondamudi</surname>
            <given-names>Noah P.</given-names>
          </name>
          <aff>Icahn School of Medicine at Mount Sinai , The Brooklyn Hospital Center</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Mahesh Borhade declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Preeti Patel declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Noah Kondamudi declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>25</day>
          <month>2</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-29014.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Sickle cell disease (SCD) is a group of inherited red blood cell disorders affecting about 1 in 500 African American children and 1 in 36,000 Hispanic American children. SCD leads to anemia and "sickle cell crisis" (SCC). The main clinical feature of sickle cell disease is the "acute painful crisis," which often requires hospitalization.&#x000a0;SCC is primarily characterized by severe acute pain and impaired end-organ function. Symptoms of SCC depend on the areas involved. Pain can begin from any part of the body but frequently affects the extremities, back, and chest areas.</p>
        <p>In a patient with SCC, evaluation is primarily performed to determine the severity of the acute disease flare. Treatment and management of SCD primarily consists of managing symptoms and associated complications.&#x000a0;This activity for healthcare professionals aims to enhance learners' competence in selecting appropriate diagnostic tests, managing sickle cell disease and associated crises, and fostering effective interprofessional teamwork to improve outcomes.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Apply knowledge of the pathophysiology of sickle cell crisis to patient assessment.</p></list-item><list-item><p>Identify&#x000a0;the complications of sickle cell disease.</p></list-item><list-item><p>Implement evidence-based treatment and management options available for sickle cell crisis.</p></list-item><list-item><p>Develop interprofessional team strategies for improving care coordination to manage sickle cell crises and improve outcomes.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=29014&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=29014">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-29014.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Sickle cell disease (SCD) is a group of inherited red blood cell disorders affecting about 1 in 500 African American children and 1 in 36,000&#x000a0;Hispanic American children.<xref ref-type="bibr" rid="article-29014.r1">[1]</xref>&#x000a0;SCD results in anemia and a "sickle cell crisis" (SCC). The main clinical feature of sickle cell disease&#x000a0;is the "acute painful crisis," which often requires hospitalization.<xref ref-type="bibr" rid="article-29014.r2">[2]</xref>&#x000a0;The term "sickle cell crisis"&#x000a0;is used to describe several acute conditions&#x000a0;such as the vaso-occlusive crisis (acute painful crisis), aplastic crisis, splenic sequestration crisis, hyperhemolytic crisis, hepatic crisis, dactylitis, and acute chest syndrome.&#x000a0;Other acute complications include pneumonia, meningitis, sepsis and&#x000a0;osteomyelitis, stroke, avascular necrosis, priapism, and venous thromboembolism.<xref ref-type="bibr" rid="article-29014.r3">[3]</xref>&#x000a0;</p>
        <p>SCC is primarily characterized by severe acute pain and impaired end-organ function. Symptoms of SCC depend on the areas involved. For instance, a vaso-occlusive crisis, which most patients with SCD experience by the age of 6 years, can cause severe pain and swelling of both hands and feet (ie, dactylitis), primarily in young children. Pain can begin from any part of the body but frequently affects the extremities, back, and chest areas. SCD is diagnosed when laboratory evaluation&#x000a0;identifies the presence of abnormal hemoglobin S (HbS). Genetic testing is also used to confirm the diagnosis. In a patient with SCC, evaluation is primarily performed to determine the severity of the acute disease flare.&#x000a0;Treatment and management of SCD primarily consists of managing symptoms and associated complications.<xref ref-type="bibr" rid="article-29014.r4">[4]</xref>&#x000a0;</p>
        <p>About a third of sickle cell disease-related deaths occur within the home setting or 24 hours of hospitalization.<xref ref-type="bibr" rid="article-29014.r5">[5]</xref>] Generally, adults are most likely to die from chronic complications, while children die acutely. The foremost causes of death in sickle cell disease are vaso-occlusive crises, cardiopulmonary threats, infections, and renal issues. Hypoxemia only compounds these problems.&#x000a0;&#x000a0;&#x000a0;</p>
      </sec>
      <sec id="article-29014.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Sickle cell disease is an autosomal recessive disorder of a gene mutation. On chromosome 11, nucleotide mutation leads to substituting glutamic acid to valine at position 6 on the &#x003b2;-globin subunit.&#x000a0;This leads to changes in the physical properties of the globin chain. Many inciting factors lead to this physical property change of red blood cells, including hypoxia, dehydration, exposure to cold or weather changes, stress, and infections.<xref ref-type="bibr" rid="article-29014.r3">[3]</xref></p>
      </sec>
      <sec id="article-29014.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Sickle cell disease affects about 3 million people worldwide and approximately 100,000 people in the US.<xref ref-type="bibr" rid="article-29014.r6">[6]</xref> The median life expectancy is 43 years. The prevalence of the disease is high among the people of sub-Saharan Africa, South Asia, the Middle East, and the Mediterranean. The most common genotype is homozygous hemoglobin SS (HbSS).<xref ref-type="bibr" rid="article-29014.r2">[2]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-29014.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>In the homozygous form of sickle cell disease, inciting triggers (eg, hypoxia, dehydration, exposure to cold or weather changes, stress) cause hemoglobin polymerization, resulting in the sickling and increased rigidity of erythrocytes.<xref ref-type="bibr" rid="article-29014.r2">[2]</xref> The subsequent deoxygenation of erythrocytes, the sickling, and now damaged red blood cells attach to the endothelial wall, forming a mass comprised of leukocytes and platelets with adhesion molecules P and E selectins. The formation of these heterocellular aggregates physically causes small vessel occlusion and resultant local hypoxia. This process triggers a vicious cycle of increased HbS formation and releases inflammatory mediators and free radicals, contributing to reperfusion injury. Hemoglobin also binds to nitric oxide (NO), a potent vasodilator, and releases oxygen.</p>
        <p>Other pathological events include increased neutrophil adhesiveness, nitric oxide binding, platelet activation, and hypercoagulability. Further microvascular occlusion occurs due to activated neutrophils. Inflammatory mediators (eg, plasma cytokines) lead to a proinflammatory state, causing further complications of vaso-occlusion. Experts postulate that the intestinal microbiome may be a potential trigger for the vaso-occlusive crisis.<xref ref-type="bibr" rid="article-29014.r7">[7]</xref>&#x000a0;While some triggers (eg, cold temperature, dehydration, low humidity, stress) for pain are identifiable, most episodes do not have an identifiable cause.<xref ref-type="bibr" rid="article-29014.r8">[8]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-29014.s6" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>
<bold>Vaso-Occlusive Crisis</bold>
</p>
        <p>Patients with vaso-occlusive crisis (VOC)<bold>&#x000a0;</bold>present with moderate to severe pain, which has variable intensity and frequency. Young children can have severe pain and swelling of both hands and feet (ie, dactylitis). Most patients with SCD experience pain by the age of 6 years. Pain can begin from any part of the body but frequently affects the extremities, back, and chest areas. Fever can accompany vaso-occlusive crisis in some patients. Although pain in patients with&#x000a0;SCD is likely to be due to VOC, performing a thorough evaluation for other life-threatening causes that can be misattributed to sickle cell pain is prudent.<xref ref-type="bibr" rid="article-29014.r9">[9]</xref> There is no objective measure or lab test to determine the quality and severity of pain in SCD; therefore, a patient's self-report is the only available guide.</p>
        <p>
<bold>Splenic Sequestration Crisis</bold>
</p>
        <p>Patients with SCD have splenic infarction before the end of childhood, rarely after age 6. The spleen is affected due to its narrow vessels and its role as a key player&#x000a0;in the lymphoreticular system. Acute splenic sequestration crisis is generally defined as acute splenic enlargement concurrent with a fall in the hemoglobin of more than 20% from the baseline in the face of a normal or increased reticulocyte count.<xref ref-type="bibr" rid="article-29014.r10">[10]</xref>&#x000a0;This happens when the spleen traps erythrocytes, leading to abdominal pain, distension, pallor, and tachycardia, followed by hypotension and lethargy. In severe cases, hypovolemic shock occurs with multiorgan failure, and death from cardiovascular collapse comes in a few hours.<xref ref-type="bibr" rid="article-29014.r11">[11]</xref><xref ref-type="bibr" rid="article-29014.r12">[12]</xref>&#x000a0;Treatment involves the resolution of any infectious trigger, administration of intravenous (IV) fluids, and blood transfusion as needed, and, for those patients with repeated attacks, a splenectomy may need consideration. If not treated promptly, this can be a life-threatening situation.<xref ref-type="bibr" rid="article-29014.r9">[9]</xref>&#x000a0;Patients with sickle cell disease are usually hyposplenic (eg, functional asplenia) and should be considered immunocompromised.<xref ref-type="bibr" rid="article-29014.r13">[13]</xref>&#x000a0;&#x000a0;</p>
        <p>
<bold>Aplastic Crisis</bold>
</p>
        <p>Aplasia in sickle crisis presents with sudden pallor and weakness confirmed by rapidly dropping hemoglobin levels accompanied by reticulocytopenia. The usual trigger for aplastic crisis is parvovirus B19, which directly suppresses the bone marrow, affecting RBC production, but other viral infections can also cause it.<xref ref-type="bibr" rid="article-29014.r12">[12]</xref> The shortened lifespan of RBC in SCD results in the worsening of the patient's baseline anemia, which can dip to dangerously low levels. There might be a slightly low platelet count and leukopenia. The infection is self-limited, typically lasting 7 to 10 days.<xref ref-type="bibr" rid="article-29014.r9">[9]</xref>&#x000a0;Aplastic crises can be handled with supportive care and simple transfusions.&#x000a0;&#x000a0;&#x000a0;</p>
        <p>
<bold>Acute Chest Syndrome</bold>
</p>
        <p>Acute chest syndrome (ACS)&#x000a0;complication of SCD accounts for 25%&#x000a0;of deaths and can follow vaso-occlusive crises. The trigger for ACS is frequently hypoxia due to hypoventilation of the chest caused by the vaso-occlusive crisis. It could also occur due to fat embolism originating from the distal bone in VOC. The hypoxia leads to the adhesion of sickled erythrocytes to pulmonary microvasculature, setting up local hypoxia in the lungs and causing the sickling of more RBCs; this sets up a vicious cycle. The presenting symptoms and signs include fever, cough, tachypnea, chest pain, hypoxia, wheezing, respiratory distress, and even failure. Any pulmonary infiltrates on chest radiography accompanied by&#x000a0;abnormal lung findings should raise suspicion of ACS. Affected&#x000a0;patients can rapidly progress to worsening respiratory failure and death if not aggressively treated and monitored.<xref ref-type="bibr" rid="article-29014.r14">[14]</xref>&#x000a0;</p>
        <p>
<bold>Hemolytic Crisis </bold>
</p>
        <p>An acute drop in hemoglobin level marks this&#x000a0;crisis. A hemolytic crisis&#x000a0;is common in patients with coexistent G6PD deficiency.<xref ref-type="bibr" rid="article-29014.r9">[9]</xref>&#x000a0; Another subset, another entity of this disorder, is known as Hyperhemolysis Syndrome.<xref ref-type="bibr" rid="article-29014.r15">[15]</xref> This is a complication of repeated blood transfusions in sickle cell disease patients. Here, hemolysis occurs in both native and donor erythrocytes. Hyperhemolysis syndrome is found within many hemoglobinopathies, although its existence in sickle cell disease is foremost. Many theories have been forwarded to explain hyperhemolysis. One belief is that erythrocytes in sickle cell disease are damaged and stressed to the extent of increased surface phosphatidyl serine. This marks then for accelerated destruction by macrophages. This accounts for the increased LDH, increased bilirubin, decreased reticulocyte count, and an unchanged Hgb A / Hbg S ratio as both the donor and the native erythrocytes are destroyed. Contrast this with delayed hemolytic transfusion reactions where the ratio is decreased as only the donor cells are lysed. The treatment is to discontinue the blood transfusion and consider giving intravenous immunoglobulin with steroids in the future.&#x000a0;&#x000a0;&#x000a0;</p>
        <p><bold>Osteonecrosis</bold>&#x000a0;</p>
        <p>Bone, as an organ, can undergo infarction in sickle cell disease, leading to osteonecrosis. Osteonecrosis affects upwards of 50% of sickle patients <xref ref-type="bibr" rid="article-29014.r16">[16]</xref>. Plain X-rays, though helpful, aren't the gold standard, as is the MRI. The MRI is superior in sensitivity, specificity, and accuracy.<xref ref-type="bibr" rid="article-29014.r17">[17]</xref>&#x000a0;Osteonecrosis in sickle cell disease appears primarily in the long bones and secondarily in sites such as the cranial sections. Osteonecrosis can be found in other ailments, too, including steroid use, HIV, SLE, renal failure, multiple sclerosis, Sjogren syndrome, COVID, SARS (Severe Acute Respiratory Syndrome), leukemias, and lymphomas. The skeletal vaso-occlusive disease leads to inflammation with cytokine release, increased receptor activation of nuclear factor Kappa-Beta Ligand (RANK) signaling, and osteoclast activation.<xref ref-type="bibr" rid="article-29014.r18">[18]</xref>&#x000a0; Osteonecrosis of the hip brings infirmity (as well as depression, anxiety, and a decreased quality of life - QOL) by causing subchondral bone collapse, leading to pain and disability.<xref ref-type="bibr" rid="article-29014.r19">[19]</xref>&#x000a0;Vitamin D deficiency also occurs in about a third of patients and compounds the situation. Protective factors for hip pathology were Hyrdrea use and high fetal hemoglobin. Some risk factors included an Hgb / Hct ratio more than 0.33 and the presence of BMP 6 (bone morphogenic protein) genotypes AT-rs267196 and AG-rs267201.<xref ref-type="bibr" rid="article-29014.r20">[20]</xref> The latter is associated with chondroblasts and osteoblasts, valuable in bone formation. The treatment approach is multifaceted. Osteoblast (ABMDO) transplantation is being sought as a means to regenerate bone and promote healing.<xref ref-type="bibr" rid="article-29014.r21">[21]</xref>&#x000a0; Intravenous bisphosphonates have been found to induce bone resorption as well as improve or resolve pain.<xref ref-type="bibr" rid="article-29014.r18">[18]</xref> As Pyrophonate analogs, osteoclasts take up bisphosphonates, thereby causing their apoptosis. Interactions can occur in any non-long bone location, such as the vertebrae, which gives the endplate an H-shaped deformity, and in the cranium. Cranial bone infarctions may involve the mandibular bone and cause facial nerve palsy; orbital infarcts may result in subgaleal hematomas.<xref ref-type="bibr" rid="article-29014.r18">[18]</xref><xref ref-type="bibr" rid="article-29014.r22">[22]</xref><xref ref-type="bibr" rid="article-29014.r23">[23]</xref> The MRI can display bone marrow edema and subperiosteal fluid. Bone infarcts can initiate a secondary effect of myositis on nearby muscles.<xref ref-type="bibr" rid="article-29014.r18">[18]</xref>&#x000a0;Creatine phosphokinase (CPK) becomes elevated and can be used as a marker for this finding. Parallel sequelae (eg, acute fasciitis, necrotizing myositis, and compartmental syndrome) can be seen.</p>
        <p>
<bold>Priapism </bold>
</p>
        <p>Priapism or unwanted penile erection occurs when there is vascular dysregulation of the exit tracts of the tunica albuginea, leading to penile engorgement.<xref ref-type="bibr" rid="article-29014.r24">[24]</xref>&#x000a0;A variety of known causes can lead to this finding, including spinal trauma, medications, and recreational substances. It affects 33% of adult males, with initiation in the prepubertal period and increasing with age. The symptoms include pain, mental stress (eg, depression and anxiety), and sexual dysfunction. Episodes lasting for more than 4 hours are a urologic emergency requiring either corporeal aspiration or shunt surgery.&#x000a0;&#x000a0;&#x000a0;</p>
        <p>
<bold>Nephropathy</bold>
</p>
        <p>Younger patients having sickle cell disease usually have an increased renal plasma flow and glomerular filtration.<xref ref-type="bibr" rid="article-29014.r25">[25]</xref> However, this degrades to normal by adulthood and decreases further to suboptimal levels with increasing age. The mechanisms involved include oxidative stress and glomerular hypertension. Additional issues compound the problem, including medullary ischemia, endothelial damage, vaso-occlusive disease, and vascular conf=gestion. Albuminuria, which is the excretion of albumin more than 300 mg/day, is the earliest manifestation, leading to the slow progression to end-stage renal disease and failure. The presence of hematuria should suggest renal medullary carcinoma. ACE-1 or ARB therapy has decreased microalbuminuria, but neither has demonstrated the ability to improve kidney function.<xref ref-type="bibr" rid="article-29014.r6">[6]</xref>&#x000a0;Hydrea improves glomerular function and, like ACE medications, can improve albuminuria and slow its progression.<xref ref-type="bibr" rid="article-29014.r26">[26]</xref>&#x000a0;Hemodialysis carries a 1-year mortality of about 26% after dialysis has started.<xref ref-type="bibr" rid="article-29014.r6">[6]</xref>&#x000a0;Renal transplantation does become an eventual consideration.&#x000a0;</p>
        <p>
<bold>Cere</bold>
<bold>brovascular accident</bold>
</p>
        <p>In sickle cell disease, 11% of patients have had an overt stroke by the age of 20 years; 39% have had silent strokes by the age of 18 years.<xref ref-type="bibr" rid="article-29014.r6">[6]</xref>&#x000a0;The strokes may be complicated by cerebral vasculopathy, nocturnal hypoxemia, and Moyamoya, which is vascular arteritis of the brain blocked). An overt stroke involves the large arteries, including the middle and intracranial internal carotid arteries, while silent cerebral infarcts involve penetrating arteries. An overt stroke presents with physical or sensory deficits such as pain or seizures; silent strokes present with cognitive defects. Screening is performed using magnetic resonance angiography (MRA) over magnetic resonance imaging (MRI), as the former can evaluate cerebral vasculopathy. Acute strokes are treated with red cell exchanges, while chronic strokes can be dealt with using a transfusion schedule to keep the HbS below 30%.&#x000a0;</p>
        <p>
<bold>Girdle syndrome </bold>
</p>
        <p>Though rarely observed, the Girdle syndrome is a clinical syndrome in which vaso-occlusion occurs in the lungs, liver, and mesentery with a characteristic pain in a girdle-like distribution.<xref ref-type="bibr" rid="article-29014.r27">[27]</xref><xref ref-type="bibr" rid="article-29014.r13">[13]</xref> The diagnosis of vasa-occlusive crisis-related gastrointestinal ischemia is based on the presentation of acute abdominal pain crisis, a constellation of clinical findings, and a lack of alternate explanations for the situation. An abdominal-pelvic CT with contrast may reveal the target appearance of bowel wall thickening with mucosal hyperenhancement and submucosal edema. Other cases in the literature have shown mucosal necrosis, transmural necrosis, hemorrhagic changes with edema, and thromboses in the mesenteric arteries and arterioles. The rarity of ischemic bowel in sickle cell disease might be due to the extensive collateral circulation in the mesentery and bowel wall. The collateral circulation offers a modicum of protection. Supportive care brings resolution in uncomplicated cases.<xref ref-type="bibr" rid="article-29014.r27">[27]</xref>&#x000a0;In severe cases, there may be bowel perforation requiring emergency surgery.&#x000a0;&#x000a0;&#x000a0;</p>
      </sec>
      <sec id="article-29014.s7" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>The diagnosis of SCD primarily involves laboratory studies that&#x000a0;identify the presence of abnormal HbS with confirmation by genetic testing. <xref ref-type="bibr" rid="article-29014.r4">[4]</xref>&#x000a0;However, patients with sickle cell crisis should have routine laboratory examinations, including a complete blood count with differential, a reticulocyte count, a complete metabolic panel, and liver function tests, in addition to a comprehensive clinical evaluation.&#x000a0;Imaging studies (eg, ultrasound, magnetic resonance imaging, Doppler) may be performed to evaluate for crisis complications.&#x000a0;Type and screen blood for possible transfusion if needed. Inflammatory markers, including CRP, procalcitonin, and broad cultures, may be considered for fever and identification of the source of infection.</p>
        <p>Clinicians should have a low threshold to obtain chest x-rays to facilitate early identification of ACS. An abdominal ultrasound may be considered for concerns of cholelithiasis. ABG can be obtained for hypoxemia and respiratory failure.<xref ref-type="bibr" rid="article-29014.r28">[28]</xref>&#x000a0;CT head and MRI brain would be indicated if there is suspicion of stroke.</p>
      </sec>
      <sec id="article-29014.s8" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Treatment and management of SCD primarily consists of managing symptoms and associated complications. Curative therapies such as stem cell transplant and gene editing are new, more complex, and costly. Unfortunately, nations rife with sickle cell disease may not have healthcare systems able to initiate these interventions.<xref ref-type="bibr" rid="article-29014.r29">[29]</xref></p>
        <p>
<bold>Vaso-Occlusive Crisis Management&#x000a0;</bold>
</p>
        <p>As a general rule, treatment requires an early diagnosis, prevention of complications, and management of end-organ damage.<xref ref-type="bibr" rid="article-29014.r6">[6]</xref>&#x000a0;Rapid pain assessment and initiation of analgesia should be undertaken promptly. Depending on the degree and severity of the pain, analgesic administration can be given intravenously (IV) or intranasally. Oral analgesics can be used for patients&#x000a0;who are not in severe pain and can tolerate oral medications. Generally, the type, route, and dose of the analgesic should be individualized to the patient. Most guidelines recommend early initiation of parenteral opioid analgesics, usually with morphine at 0.1 mg/kg IV or subcutaneously (SC) every 20 minutes, and maintaining this analgesia with morphine at doses of 0.05 to 0.1 mg/ kg every 2 to 4 hours (SC/IV or orally). Those with persistent pain benefit from a PCA pump. Close monitoring of vital signs, including oxygen saturation, should be maintained with frequent pain severity or resolution reassessments.<xref ref-type="bibr" rid="article-29014.r28">[28]</xref>&#x000a0;If the pain is controlled, the patient may be ready for discharge with a home care plan and oral analgesia.<xref ref-type="bibr" rid="article-29014.r30">[30]</xref>&#x000a0;If the pain is uncontrolled despite the above treatment plan, consider hospitalization and the use of more potent forms of analgesia or higher doses titrated to the patient's needs. Simple or exchange transfusion may be warranted.<xref ref-type="bibr" rid="article-29014.r31">[31]</xref></p>
        <p>Maintaining adequate hydration and being vigilant in identifying other causes of pain that may need additional treatment is prudent. Dehydration is one of the known factors of venous-occlusive disease, caused by the formation of deoxygenated HbS (deoxyHbs), which causes increased adherence and decreased flexibility of the erythrocytes. Plasma concentration is a function of the intracellular content of deoxy HbS. The sickling of erythrocytes depends on both factors. This is why patients who present with a painful crisis should be given fluids to slow down or stop the sickling process. Increasing the plasma volume decreases blood viscosity and indirectly reduces the amount and concentration of HbS within the red blood cells.&#x000a0;</p>
        <p>For other entities like acute chest syndrome, splenic sequestration-supportive care with oxygen, judicious fluid administration, and transfusion therapy are needed. Close monitoring of oxygen saturation and respiratory status is also necessary, with particular attention to excessive sedation.<xref ref-type="bibr" rid="article-29014.r32">[32]</xref>&#x000a0;Empiric antibiotics, adequate analgesics, and simple or exchange transfusion may be considered for acute chest syndrome. Incentive spirometry, oral hydration, and comfort measures are recommended. Patients with splenic sequestration crisis resulting in hypovolemic shock, if not treated aggressively, have higher mortality. Management requires aggressive supportive care and blood transfusion.<xref ref-type="bibr" rid="article-29014.r28">[28]</xref> &#x000a0;</p>
        <p>Hydrea is an antimetabolite, a chemotherapy agent, that is foremost in treating sickle cell disease by&#x000a0;augmenting HbF levels within the red blood cells. This mechanism decreases the rate of acute chest syndrome, pain, and other sequelae.<xref ref-type="bibr" rid="article-29014.r33">[33]</xref>&#x000a0;As a result, the quality of life is improved, hospitalizations are lessened, and transfusion needs are reduced.<xref ref-type="bibr" rid="article-29014.r34">[34]</xref>&#x000a0;Glutamine is required to synthesize amino acids that protect the erythrocyte against oxidative damage.<xref ref-type="bibr" rid="article-29014.r6">[6]</xref>&#x000a0;It does so by increasing the availability of Nicotinamide Adenine Dinucleotide (NAD), a redox factor.<xref ref-type="bibr" rid="article-29014.r5">[5]</xref>&#x000a0;NAD does not affect the Hgb, Hct, or reticulocyte count. Experts believe NAT reinstates the intestinal barrier, prohibiting bacterial entry.<xref ref-type="bibr" rid="article-29014.r35">[35]</xref> These microbial interlopers are believed to compound the inflammation that promotes vaso-occlusive crises. Vaxelotor modifies HbS so that its polymerization is obstructed and its oxygen affinity increases.<xref ref-type="bibr" rid="article-29014.r6">[6]</xref><xref ref-type="bibr" rid="article-29014.r5">[5]</xref>&#x000a0; It improves hemolysis but has little effect on the sickle crisis. Vaxelotor effects with glutamine are synergistic; its effects with crizanlizumab are antagonistic. As an oxygen affinity modulator, vaxelotor reportedly has a relatively good safety profile and is used foremost in Europe.<xref ref-type="bibr" rid="article-29014.r36">[36]</xref>&#x000a0;Crizanlizumab is a humanized monoclonal antibody&#x000a0;gG-2 Kappa that blocks P-selectin, the binding protein of sickle cells.<xref ref-type="bibr" rid="article-29014.r5">[5]</xref><xref ref-type="bibr" rid="article-29014.r6">[6]</xref>&#x000a0;By doing so, crizanlizumab interrupts the vaso-occlusive process. It additionally blocks the adhesion of neutrophils and activated platelets.<xref ref-type="bibr" rid="article-29014.r36">[36]</xref>&#x000a0;Crizanlizumab is administered by monthly infusion.</p>
        <p>Bone marrow transplant (BMT) has curative potential in sickle cell disease.<xref ref-type="bibr" rid="article-29014.r6">[6]</xref>&#x000a0;Hematologic stem cell transplant (HSCT) with HLA-matched sibling donors and either myeloablative or reduced-intensity conditioning regimens have a 5-year overall survival (OS) of about 90%. Matched unrelated transplants have difficulties with GVHD as high as 29%. Haploidentical HSCT, with posttransplant cyclophosphamide, has some utility. Umbilical cord transplant has shortcomings in terms of a low transplant cell dose and, if from an unmatched donor, the increased risk of graft rejection and GVHD. Gene therapy, with autologous transplantation, is developing into a possible modality for sickle cell treatment.<xref ref-type="bibr" rid="article-29014.r37">[37]</xref>&#x000a0;Functional human beta-globin genes (eg, Lentiglobin) are inserted ex-vivo into a patient's stem cells which are then transplanted back into the patient. These patients then produce HbA and have noteworthy reductions in hemolysis and vaso-occlusive crises.&#x000a0;</p>
        <p>Long-term management of sickle cell disease is focused on the prevention of infection as well as the prevention of end-organ damage.<xref ref-type="bibr" rid="article-29014.r13">[13]</xref> Besides lifelong administration of penicillin V, vaccinations against meningococcus, pneumococcus, and hemophilus influenza B are available to prevent infection with encapsulated organisms. COVID-19 and influenza vaccinations should be encouraged. Folate supplementation helps prevent a functional folate deficit.&#x000a0;&#x000a0;&#x000a0;</p>
      </sec>
      <sec id="article-29014.s9" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Vaso-occlusive crisis presents with severe pain with a relative lack of objective clinical signs. Differential diagnosis should include conditions specific to the site of the pain and not be blindly attributed to sickle cell disease. As an example, patients presenting with an abdominal painful crisis can mimic an acute abdomen, and the differential should include conditions that give acute abdominal pain, including acute appendicitis, acute pancreatitis, acute pyelonephritis, pelvic inflammatory disease, and hepatobiliary disease. Avascular necrosis and acute osteomyelitis are a consideration when there is persistent local bone pain.</p>
      </sec>
      <sec id="article-29014.s10" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>Predictors of multiorgan failure in chest crises include thrombocytopenia, anemia, an increased respiratory rate, worsening hypoxia, multilobar chest x-ray involvement, and neurogenic compromise.<xref ref-type="bibr" rid="article-29014.r13">[13]</xref>&#x000a0;As infection can trigger a chest crisis, checking blood and sputum cultures if needed and nasopharyngeal aspirates for respiratory viruses is best.&#x000a0;&#x000a0;</p>
      </sec>
      <sec id="article-29014.s11" sec-type="Complications">
        <title>Complications</title>
        <p>The&#x000a0;adverse effects of therapy or its failure are a complication of the sickle patient; the damage is cumulative. The 3 most frequent complications of vaso-occlusive crises are infections, fever, and pulmonary problems.<xref ref-type="bibr" rid="article-29014.r38">[38]</xref>&#x000a0;The patient's activity, capacity, and reserve undergo a diminution with time. Neurogenic complications in sickle cell disease include silent cerebral ischemia, ischemic or hemorrhagic stroke, Moyamoya syndrome, posterior reversible encephalopathy syndrome, cerebral fat embolism, and cerebral venous sinus thrombosis.<xref ref-type="bibr" rid="article-29014.r39">[39]</xref>&#x000a0;</p>
        <p>Bacterial infections remain frequent and a severe complication of sickle cell disease.<xref ref-type="bibr" rid="article-29014.r40">[40]</xref> Sickling leads to functional asplenia that leaves the patients at risk for life-threatening infections, especially from encapsulated microbes such as <italic toggle="yes">Streptococcus pneumoniae, Neisseria meningitides</italic>, and <italic toggle="yes">Haemophilus influenza</italic> type b. Some world areas incur additional infectious hazards like hepatitis B, salmonella, and malaria.<xref ref-type="bibr" rid="article-29014.r41">[41]</xref>&#x000a0;Tragically, poverty and the lack of health care support only magnify these problems.&#x000a0;</p>
        <p>Treatment is known, but there is a lack of presence. Acute chest syndrome is the leading cause of death in sickle adults. Infectious causes predominate here, including mycoplasma pneumonia and respiratory syncytial virus (RSV), which are common in children; chlamydia is common in adults. Stroke is the leading cause of disability in sickle cell patients.<xref ref-type="bibr" rid="article-29014.r40">[40]</xref>&#x000a0;Ischemic stroke occurs primarily in children, whereas cerebral hemorrhage occurs primarily in adults of the ages of 30s to 40s. Once an acute stroke develops, an exchange transfusion protocol should be started without delay. After a stroke, there is a high probability of recurrence unless these transfusion protocols are initiated. Transfusions are indicated in acute chest syndrome, stroke, aplasia, and sequestration problems. However, the risks include alloimmunization, delayed hemolytic transfusion reaction, hyperviscosity, and iron overload.&#x000a0;&#x000a0;&#x000a0;</p>
      </sec>
      <sec id="article-29014.s12" sec-type="Consultations">
        <title>Consultations</title>
        <p>Consultation with a hematologist is helpful.&#x000a0;</p>
      </sec>
      <sec id="article-29014.s13" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Patient medical education can prevent the need for more aggressive intervention later because the patient can monitor their condition and report crisis symptoms as they initially develop. While patients may not be medically trained, they and their caretakers can be taught what to observe and how to react. Sickle cell crises can cause cumulative damage. The sooner they can be settled, the better the long-term quality of life for the patient.</p>
      </sec>
      <sec id="article-29014.s14" sec-type="Pearls and Other Issues">
        <title>Pearls and Other Issues</title>
        <p>Early detection and rapid initiation of appropriate treatment for&#x000a0;several acute conditions, including vaso-occlusive, aplastic, sequestration, and hemolytic crises, is needed. These crises, if not treated early, can result in mortality.</p>
      </sec>
      <sec id="article-29014.s15" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>SCD&#x000a0;is a hereditary hemoglobinopathy characterized by abnormal, crescent-shaped red blood cells, leading to vaso-occlusive crises, anemia, and organ damage. Clinicians must recognize the diverse clinical manifestations, including pain crises, acute chest syndrome, and stroke. Comprehensive care involves hydroxyurea for symptom management, transfusions for complications, and potentially curative stem cell transplantation. Regular monitoring, vaccination, and patient education are crucial for preventing and managing complications. An&#x000a0;interdisciplinary&#x000a0;approach, considering both acute crises and long-term complications, is vital for optimizing outcomes in individuals with SCD.</p>
        <p>Patients with sickle cell crises are best managed by an interprofessional team that includes specialist and primary care physicians, nurses, pharmacists, physical therapists, radiology and laboratory technicians, and genetic counselors. The key is rapid hydration and pain control. In addition, oxygenation should be monitored. Finding and treating the trigger of the crisis is critical to prevent a recurrent crisis.&#x000a0;Despite optimal treatment, the quality of life of most patients with sickle cell is poor, marked by repeated admissions. The pharmacist should ensure that the patient complies with hydroxyurea because it has been shown to reduce the adverse effects of the disease.</p>
      </sec>
      <sec id="article-29014.s16">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=29014&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=29014">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/health/sickle-cell-crisis/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=29014">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/29014/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=29014">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-29014.s17">
        <title>References</title>
        <ref id="article-29014.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lim</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Fast</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Morris</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Sickle cell vaso-occlusive crisis: it's a gut feeling.</article-title>
            <source>J Transl Med</source>
            <year>2016</year>
            <month>Dec</month>
            <day>01</day>
            <volume>14</volume>
            <issue>1</issue>
            <fpage>334</fpage>
            <pub-id pub-id-type="pmid">27906010</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29014.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jeremiah</surname>
                <given-names>ZA</given-names>
              </name>
            </person-group>
            <article-title>Abnormal haemoglobin variants, ABO and Rh blood groups among student of African descent in Port Harcourt, Nigeria.</article-title>
            <source>Afr Health Sci</source>
            <year>2006</year>
            <month>Sep</month>
            <volume>6</volume>
            <issue>3</issue>
            <fpage>177</fpage>
            <page-range>177-81</page-range>
            <pub-id pub-id-type="pmid">17140342</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29014.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hiran</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Multiorgan dysfunction syndrome in sickle cell disease.</article-title>
            <source>J Assoc Physicians India</source>
            <year>2005</year>
            <month>Jan</month>
            <volume>53</volume>
            <fpage>19</fpage>
            <page-range>19-22</page-range>
            <pub-id pub-id-type="pmid">15857006</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29014.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Elendu</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Amaechi</surname>
                <given-names>DC</given-names>
              </name>
              <name>
                <surname>Alakwe-Ojimba</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Elendu</surname>
                <given-names>TC</given-names>
              </name>
              <name>
                <surname>Elendu</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Ayabazu</surname>
                <given-names>CP</given-names>
              </name>
              <name>
                <surname>Aina</surname>
                <given-names>TO</given-names>
              </name>
              <name>
                <surname>Aborisade</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Adenikinju</surname>
                <given-names>JS</given-names>
              </name>
            </person-group>
            <article-title>Understanding Sickle cell disease: Causes, symptoms, and treatment options.</article-title>
            <source>Medicine (Baltimore)</source>
            <year>2023</year>
            <month>Sep</month>
            <day>22</day>
            <volume>102</volume>
            <issue>38</issue>
            <fpage>e35237</fpage>
            <pub-id pub-id-type="pmid">37746969</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29014.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dick</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Abdelgadir</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kulkarni</surname>
                <given-names>VV</given-names>
              </name>
              <name>
                <surname>Akram</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Chatterjee</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Pokhrel</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Khan</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Comparing the Safety and Efficacy of L-Glutamine, Voxelotor, and Crizanlizumab for Reducing the Frequency of Vaso-Occlusive Crisis in Sickle Cell Disease: A Systematic Review.</article-title>
            <source>Cureus</source>
            <year>2022</year>
            <month>May</month>
            <volume>14</volume>
            <issue>5</issue>
            <fpage>e24920</fpage>
            <pub-id pub-id-type="pmid">35706735</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29014.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brandow</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Liem</surname>
                <given-names>RI</given-names>
              </name>
            </person-group>
            <article-title>Advances in the diagnosis and treatment of sickle cell disease.</article-title>
            <source>J Hematol Oncol</source>
            <year>2022</year>
            <month>Mar</month>
            <day>03</day>
            <volume>15</volume>
            <issue>1</issue>
            <fpage>20</fpage>
            <pub-id pub-id-type="pmid">35241123</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29014.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mehta</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Afenyi-Annan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Byrns</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Lottenberg</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Opportunities to improve outcomes in sickle cell disease.</article-title>
            <source>Am Fam Physician</source>
            <year>2006</year>
            <month>Jul</month>
            <day>15</day>
            <volume>74</volume>
            <issue>2</issue>
            <fpage>303</fpage>
            <page-range>303-10</page-range>
            <pub-id pub-id-type="pmid">16883928</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29014.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Porter</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Rapid Fire: Sickle Cell Disease.</article-title>
            <source>Emerg Med Clin North Am</source>
            <year>2018</year>
            <month>Aug</month>
            <volume>36</volume>
            <issue>3</issue>
            <fpage>567</fpage>
            <page-range>567-576</page-range>
            <pub-id pub-id-type="pmid">30037443</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29014.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Quinn</surname>
                <given-names>CT</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>NJ</given-names>
              </name>
              <name>
                <surname>Shull</surname>
                <given-names>EP</given-names>
              </name>
              <name>
                <surname>Ahmad</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Rogers</surname>
                <given-names>ZR</given-names>
              </name>
              <name>
                <surname>Buchanan</surname>
                <given-names>GR</given-names>
              </name>
            </person-group>
            <article-title>Prediction of adverse outcomes in children with sickle cell anemia: a study of the Dallas Newborn Cohort.</article-title>
            <source>Blood</source>
            <year>2008</year>
            <month>Jan</month>
            <day>15</day>
            <volume>111</volume>
            <issue>2</issue>
            <fpage>544</fpage>
            <page-range>544-8</page-range>
            <pub-id pub-id-type="pmid">17909076</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29014.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brousse</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Buffet</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Rees</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>The spleen and sickle cell disease: the sick(led) spleen.</article-title>
            <source>Br J Haematol</source>
            <year>2014</year>
            <month>Jul</month>
            <volume>166</volume>
            <issue>2</issue>
            <fpage>165</fpage>
            <page-range>165-76</page-range>
            <pub-id pub-id-type="pmid">24862308</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29014.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>de la Hoz</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Otones</surname>
                <given-names>LL</given-names>
              </name>
              <name>
                <surname>S&#x000e1;enz</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Mart&#x000ed;n</surname>
                <given-names>MJR</given-names>
              </name>
            </person-group>
            <article-title>Parvovirus b19 infection in children with sickle cell disease, watch out for splenomegaly! A case report.</article-title>
            <source>Afr Health Sci</source>
            <year>2022</year>
            <month>Mar</month>
            <volume>22</volume>
            <issue>1</issue>
            <fpage>598</fpage>
            <page-range>598-601</page-range>
            <pub-id pub-id-type="pmid">36032454</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29014.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Beck</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Trottier</surname>
                <given-names>ED</given-names>
              </name>
              <name>
                <surname>Kirby-Allen</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pastore</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Acute complications in children with sickle cell disease: Prevention and management.</article-title>
            <source>Paediatr Child Health</source>
            <year>2022</year>
            <month>Mar</month>
            <volume>27</volume>
            <issue>1</issue>
            <fpage>50</fpage>
            <page-range>50-62</page-range>
            <pub-id pub-id-type="pmid">35273671</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29014.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Conway O'Brien</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Ali</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Chevassut</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Sickle cell disease: an update.</article-title>
            <source>Clin Med (Lond)</source>
            <year>2022</year>
            <month>May</month>
            <volume>22</volume>
            <issue>3</issue>
            <fpage>218</fpage>
            <page-range>218-220</page-range>
            <pub-id pub-id-type="pmid">35584832</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29014.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hebbel</surname>
                <given-names>RP</given-names>
              </name>
              <name>
                <surname>Boogaerts</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Eaton</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Steinberg</surname>
                <given-names>MH</given-names>
              </name>
            </person-group>
            <article-title>Erythrocyte adherence to endothelium in sickle-cell anemia. A possible determinant of disease severity.</article-title>
            <source>N Engl J Med</source>
            <year>1980</year>
            <month>May</month>
            <day>01</day>
            <volume>302</volume>
            <issue>18</issue>
            <fpage>992</fpage>
            <page-range>992-5</page-range>
            <pub-id pub-id-type="pmid">7366623</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29014.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Trivedi</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Abbas</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kazmi</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Shaaban</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Hyperhemolytic Crisis Following Transfusion in Sickle Cell Disease With Acute Hepatic Crisis: A Case Report.</article-title>
            <source>Cureus</source>
            <year>2022</year>
            <month>Aug</month>
            <volume>14</volume>
            <issue>8</issue>
            <fpage>e27844</fpage>
            <pub-id pub-id-type="pmid">36110470</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29014.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pereira</surname>
                <given-names>TCS</given-names>
              </name>
              <name>
                <surname>Souza</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Daltro</surname>
                <given-names>PB</given-names>
              </name>
              <name>
                <surname>Carosio</surname>
                <given-names>MGA</given-names>
              </name>
              <name>
                <surname>Ferreira</surname>
                <given-names>AG</given-names>
              </name>
              <name>
                <surname>Oliveira</surname>
                <given-names>RV</given-names>
              </name>
              <name>
                <surname>Fortuna</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Ribeiro</surname>
                <given-names>PR</given-names>
              </name>
            </person-group>
            <article-title>Blood plasma and bone marrow interstitial fluid metabolomics of sickle cell disease patients with osteonecrosis: An exploratory study to dissect biochemical alterations.</article-title>
            <source>Clin Chim Acta</source>
            <year>2023</year>
            <month>Jan</month>
            <day>15</day>
            <volume>539</volume>
            <fpage>18</fpage>
            <page-range>18-25</page-range>
            <pub-id pub-id-type="pmid">36450311</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29014.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hussein</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>Jan</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Alharbi</surname>
                <given-names>LK</given-names>
              </name>
              <name>
                <surname>Khalil</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Abdelrahman</surname>
                <given-names>AI</given-names>
              </name>
              <name>
                <surname>El Sayed</surname>
                <given-names>SM</given-names>
              </name>
            </person-group>
            <article-title>Rheumatological picture of a patient having multifocal osteonecrosis associated with sickle cell anemia: a case study.</article-title>
            <source>Am J Blood Res</source>
            <year>2022</year>
            <volume>12</volume>
            <issue>4</issue>
            <fpage>156</fpage>
            <page-range>156-162</page-range>
            <pub-id pub-id-type="pmid">36147607</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29014.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Grimbly</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Escagedo</surname>
                <given-names>PD</given-names>
              </name>
              <name>
                <surname>Jaremko</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Bruce</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Alos</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Robinson</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Konji</surname>
                <given-names>VN</given-names>
              </name>
              <name>
                <surname>Page</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Scharke</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Simpson</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Pastore</surname>
                <given-names>YD</given-names>
              </name>
              <name>
                <surname>Girgis</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Alexander</surname>
                <given-names>RT</given-names>
              </name>
              <name>
                <surname>Ward</surname>
                <given-names>LM</given-names>
              </name>
            </person-group>
            <article-title>Sickle cell bone disease and response to intravenous bisphosphonates in children.</article-title>
            <source>Osteoporos Int</source>
            <year>2022</year>
            <month>Nov</month>
            <volume>33</volume>
            <issue>11</issue>
            <fpage>2397</fpage>
            <page-range>2397-2408</page-range>
            <pub-id pub-id-type="pmid">35904681</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29014.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Leandro</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>De S&#x000e1;</surname>
                <given-names>CKC</given-names>
              </name>
              <name>
                <surname>Filho</surname>
                <given-names>DPS</given-names>
              </name>
              <name>
                <surname>De Souza</surname>
                <given-names>LAA</given-names>
              </name>
              <name>
                <surname>Salles</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Ten&#x000f3;rio</surname>
                <given-names>MCC</given-names>
              </name>
              <name>
                <surname>Paz</surname>
                <given-names>CLDSL</given-names>
              </name>
              <name>
                <surname>Matos</surname>
                <given-names>MAA</given-names>
              </name>
            </person-group>
            <article-title>Association and Risk Factors of Osteonecrosis of Femoral Head in Sickle Cell Disease: A Systematic Review.</article-title>
            <source>Indian J Orthop</source>
            <year>2022</year>
            <month>Feb</month>
            <volume>56</volume>
            <issue>2</issue>
            <fpage>216</fpage>
            <page-range>216-225</page-range>
            <pub-id pub-id-type="pmid">35140852</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29014.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chaouch</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Kalai</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Jbara</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Chaabene</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Darragi</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Chaouachi</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Mallouli</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Hafsia</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Ghanem</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Abbes</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Association between rs267196 and rs267201 of BMP6 gene and osteonecrosis among sickle cell aneamia patients.</article-title>
            <source>Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub</source>
            <year>2015</year>
            <month>Mar</month>
            <volume>159</volume>
            <issue>1</issue>
            <fpage>145</fpage>
            <page-range>145-9</page-range>
            <pub-id pub-id-type="pmid">24263212</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29014.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sadat-Ali</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Al-Omran</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>AlTabash</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Acharya</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hegazi</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Al Muhaish</surname>
                <given-names>MI</given-names>
              </name>
            </person-group>
            <article-title>The clinical and radiological effectiveness of autologous bone marrow derived osteoblasts (ABMDO) in the management of avascular necrosis of femoral head (ANFH) in sickle cell disease (SCD).</article-title>
            <source>J Exp Orthop</source>
            <year>2022</year>
            <month>Feb</month>
            <day>17</day>
            <volume>9</volume>
            <issue>1</issue>
            <fpage>18</fpage>
            <pub-id pub-id-type="pmid">35178642</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29014.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Watanabe</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Saito</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Nadgir</surname>
                <given-names>RN</given-names>
              </name>
              <name>
                <surname>Liao</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Flower</surname>
                <given-names>EN</given-names>
              </name>
              <name>
                <surname>Steinberg</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Sakai</surname>
                <given-names>O</given-names>
              </name>
            </person-group>
            <article-title>Craniofacial bone infarcts in sickle cell disease: clinical and radiological manifestations.</article-title>
            <source>J Comput Assist Tomogr</source>
            <year>2013</year>
            <season>Jan-Feb</season>
            <volume>37</volume>
            <issue>1</issue>
            <fpage>91</fpage>
            <page-range>91-7</page-range>
            <pub-id pub-id-type="pmid">23321839</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29014.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Arends</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Coebergh</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Kerkhoffs</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>van Gils</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Koppen</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Severe unilateral headache caused by skull bone infarction with epidural haematoma in a patient with sickle cell disease.</article-title>
            <source>Cephalalgia</source>
            <year>2011</year>
            <month>Sep</month>
            <volume>31</volume>
            <issue>12</issue>
            <fpage>1325</fpage>
            <page-range>1325-8</page-range>
            <pub-id pub-id-type="pmid">21803935</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29014.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Idris</surname>
                <given-names>IM</given-names>
              </name>
              <name>
                <surname>Burnett</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>DeBaun</surname>
                <given-names>MR</given-names>
              </name>
            </person-group>
            <article-title>Epidemiology and treatment of priapism in sickle cell disease.</article-title>
            <source>Hematology Am Soc Hematol Educ Program</source>
            <year>2022</year>
            <month>Dec</month>
            <day>09</day>
            <volume>2022</volume>
            <issue>1</issue>
            <fpage>450</fpage>
            <page-range>450-458</page-range>
            <pub-id pub-id-type="pmid">36485155</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29014.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ataga</surname>
                <given-names>KI</given-names>
              </name>
              <name>
                <surname>Saraf</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Derebail</surname>
                <given-names>VK</given-names>
              </name>
            </person-group>
            <article-title>The nephropathy of sickle cell trait and sickle cell disease.</article-title>
            <source>Nat Rev Nephrol</source>
            <year>2022</year>
            <month>Jun</month>
            <volume>18</volume>
            <issue>6</issue>
            <fpage>361</fpage>
            <page-range>361-377</page-range>
            <pub-id pub-id-type="pmid">35190716</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29014.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hariri</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Mansour</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>El Alam</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Daaboul</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Korjian</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Aoun Bahous</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Sickle cell nephropathy: an update on pathophysiology, diagnosis, and treatment.</article-title>
            <source>Int Urol Nephrol</source>
            <year>2018</year>
            <month>Jun</month>
            <volume>50</volume>
            <issue>6</issue>
            <fpage>1075</fpage>
            <page-range>1075-1083</page-range>
            <pub-id pub-id-type="pmid">29383580</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29014.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gautam</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Harmon</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Foley</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Gastrointestinal vaso-occlusive crisis in sickle cell disease.</article-title>
            <source>Proc (Bayl Univ Med Cent)</source>
            <year>2022</year>
            <volume>35</volume>
            <issue>6</issue>
            <fpage>856</fpage>
            <page-range>856-857</page-range>
            <pub-id pub-id-type="pmid">36304615</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29014.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chou</surname>
                <given-names>ST</given-names>
              </name>
              <name>
                <surname>Fasano</surname>
                <given-names>RM</given-names>
              </name>
            </person-group>
            <article-title>Management of Patients with Sickle Cell Disease Using Transfusion Therapy: Guidelines and Complications.</article-title>
            <source>Hematol Oncol Clin North Am</source>
            <year>2016</year>
            <month>Jun</month>
            <volume>30</volume>
            <issue>3</issue>
            <fpage>591</fpage>
            <page-range>591-608</page-range>
            <pub-id pub-id-type="pmid">27112998</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29014.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mary Nnagha</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Kayode Ademola</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ann Izevbizua</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Uwishema</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Nazir</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Wellington</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Tackling sickle cell crisis in Nigeria: the need for newer therapeutic solutions in sickle cell crisis management - short communication.</article-title>
            <source>Ann Med Surg (Lond)</source>
            <year>2023</year>
            <month>May</month>
            <volume>85</volume>
            <issue>5</issue>
            <fpage>2282</fpage>
            <page-range>2282-2286</page-range>
            <pub-id pub-id-type="pmid">37228913</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29014.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ballas</surname>
                <given-names>SK</given-names>
              </name>
            </person-group>
            <article-title>Current issues in sickle cell pain and its management.</article-title>
            <source>Hematology Am Soc Hematol Educ Program</source>
            <year>2007</year>
            <fpage>97</fpage>
            <page-range>97-105</page-range>
            <pub-id pub-id-type="pmid">18024616</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29014.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Robieux</surname>
                <given-names>IC</given-names>
              </name>
              <name>
                <surname>Kellner</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Coppes</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Shaw</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Good</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>O'Brodovich</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Manson</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Olivieri</surname>
                <given-names>NF</given-names>
              </name>
              <name>
                <surname>Zipursky</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Analgesia in children with sickle cell crisis: comparison of intermittent opioids vs. continuous intravenous infusion of morphine and placebo-controlled study of oxygen inhalation.</article-title>
            <source>Pediatr Hematol Oncol</source>
            <year>1992</year>
            <season>Oct-Dec</season>
            <volume>9</volume>
            <issue>4</issue>
            <fpage>317</fpage>
            <page-range>317-26</page-range>
            <pub-id pub-id-type="pmid">1467165</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29014.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Simon</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Long</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Koyfman</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Emergency Medicine Management of Sickle Cell Disease Complications: An Evidence-Based Update.</article-title>
            <source>J Emerg Med</source>
            <year>2016</year>
            <month>Oct</month>
            <volume>51</volume>
            <issue>4</issue>
            <fpage>370</fpage>
            <page-range>370-381</page-range>
            <pub-id pub-id-type="pmid">27553919</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29014.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Akindele</surname>
                <given-names>AO</given-names>
              </name>
              <name>
                <surname>Jalkh</surname>
                <given-names>AP</given-names>
              </name>
              <name>
                <surname>Eastmond</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Shetty</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Rizvi</surname>
                <given-names>SMHA</given-names>
              </name>
              <name>
                <surname>Sharaf</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>KD</given-names>
              </name>
              <name>
                <surname>Tariq</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Acharekar</surname>
                <given-names>MV</given-names>
              </name>
              <name>
                <surname>Guerrero Saldivia</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Unnikrishnan</surname>
                <given-names>SN</given-names>
              </name>
              <name>
                <surname>Chavarria</surname>
                <given-names>YY</given-names>
              </name>
              <name>
                <surname>Balani</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Treatment Options That Reduce the Duration of Sickle Cell Vaso-Occlusive Crises: A Systematic Review.</article-title>
            <source>Cureus</source>
            <year>2022</year>
            <month>Aug</month>
            <volume>14</volume>
            <issue>8</issue>
            <fpage>e28337</fpage>
            <pub-id pub-id-type="pmid">36176876</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29014.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Alkhalifah</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Alanazi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Almasaoud</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Al-Malki</surname>
                <given-names>HS</given-names>
              </name>
              <name>
                <surname>Al-Murdhi</surname>
                <given-names>FM</given-names>
              </name>
              <name>
                <surname>Al-Hazzaa</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Al-Mufarrij</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Albabtain</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Alshiakh</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>AlRuthia</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>The impact of Hydroxyurea on the rates of Vaso-occlusive crises in patients with sickle cell disease in Saudi Arabia: a single-center study.</article-title>
            <source>BMC Emerg Med</source>
            <year>2022</year>
            <month>Nov</month>
            <day>29</day>
            <volume>22</volume>
            <issue>1</issue>
            <fpage>188</fpage>
            <pub-id pub-id-type="pmid">36447134</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29014.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jang</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Poplawska</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Cimpeanu</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Mo</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Dutta</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Lim</surname>
                <given-names>SH</given-names>
              </name>
            </person-group>
            <article-title>Vaso-occlusive crisis in sickle cell disease: a vicious cycle of secondary events.</article-title>
            <source>J Transl Med</source>
            <year>2021</year>
            <month>Sep</month>
            <day>20</day>
            <volume>19</volume>
            <issue>1</issue>
            <fpage>397</fpage>
            <pub-id pub-id-type="pmid">34544432</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29014.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Abdel-Hadi</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Ventura Carmenate</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Castillo-Aleman</surname>
                <given-names>YM</given-names>
              </name>
              <name>
                <surname>Sheikh</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Zakaria</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Phillips</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Treatment of sickle cell disease - options and perspective.</article-title>
            <source>Am J Blood Res</source>
            <year>2023</year>
            <volume>13</volume>
            <issue>2</issue>
            <fpage>61</fpage>
            <page-range>61-70</page-range>
            <pub-id pub-id-type="pmid">37214647</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29014.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kanter</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Walters</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Krishnamurti</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Mapara</surname>
                <given-names>MY</given-names>
              </name>
              <name>
                <surname>Kwiatkowski</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Rifkin-Zenenberg</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Aygun</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Kasow</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Pierciey</surname>
                <given-names>FJ</given-names>
              </name>
              <name>
                <surname>Bonner</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Lynch</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Ribeil</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Asmal</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Goyal</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Thompson</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Tisdale</surname>
                <given-names>JF</given-names>
              </name>
            </person-group>
            <article-title>Biologic and Clinical Efficacy of LentiGlobin for Sickle Cell Disease.</article-title>
            <source>N Engl J Med</source>
            <year>2022</year>
            <month>Feb</month>
            <day>17</day>
            <volume>386</volume>
            <issue>7</issue>
            <fpage>617</fpage>
            <page-range>617-628</page-range>
            <pub-id pub-id-type="pmid">34898139</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29014.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shah</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Bhor</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Xie</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Paulose</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Yuce</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Sickle cell disease complications: Prevalence and resource utilization.</article-title>
            <source>PLoS One</source>
            <year>2019</year>
            <volume>14</volume>
            <issue>7</issue>
            <fpage>e0214355</fpage>
            <pub-id pub-id-type="pmid">31276525</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29014.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Farooq</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Testai</surname>
                <given-names>FD</given-names>
              </name>
            </person-group>
            <article-title>Neurologic Complications of Sickle Cell Disease.</article-title>
            <source>Curr Neurol Neurosci Rep</source>
            <year>2019</year>
            <month>Feb</month>
            <day>28</day>
            <volume>19</volume>
            <issue>4</issue>
            <fpage>17</fpage>
            <pub-id pub-id-type="pmid">30820687</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29014.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Abboud</surname>
                <given-names>MR</given-names>
              </name>
            </person-group>
            <article-title>Standard management of sickle cell disease complications.</article-title>
            <source>Hematol Oncol Stem Cell Ther</source>
            <year>2020</year>
            <month>Jun</month>
            <volume>13</volume>
            <issue>2</issue>
            <fpage>85</fpage>
            <page-range>85-90</page-range>
            <pub-id pub-id-type="pmid">32202245</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29014.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Aloni</surname>
                <given-names>MN</given-names>
              </name>
              <name>
                <surname>Kadima</surname>
                <given-names>BT</given-names>
              </name>
              <name>
                <surname>Ekulu</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Budiongo</surname>
                <given-names>AN</given-names>
              </name>
              <name>
                <surname>Ngiyulu</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Gini-Ehungu</surname>
                <given-names>JL</given-names>
              </name>
            </person-group>
            <article-title>Acute Crises and Complications of Sickle Cell Anemia Among Patients Attending a Pediatric Tertiary Unit in Kinshasa, Democratic Republic Of Congo.</article-title>
            <source>Hematol Rep</source>
            <year>2017</year>
            <month>Jun</month>
            <day>01</day>
            <volume>9</volume>
            <issue>2</issue>
            <fpage>6952</fpage>
            <pub-id pub-id-type="pmid">28626540</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
